BACKGROUND: Pneumococcal colonization of the nasopharynx is especially common in young children and is a pre-requisite for pneumococcal disease. Those with immunosuppression, such as HIV, are at higher risk of colonization and disease, especially at older ages. Currently, vaccination schedules are only offered to children under 6 months of age, despite the large impact of pneumococcal disease in older unvaccinated children with HIV. We conducted a study to assess the prevalence of, and risk factors for, pneumococcal carriage in HIV-positive children aged <15 years. METHODS: We collected a single nasopharyngeal swab from 142 HIV-infected children aged 1-14 years over a 2-month period. To detect carriage of pneumococcus, these samples were cultured and serotyped; PCR was performed on negative samples. We also collected epidemiological data via survey and medical records. RESULTS: The overall carriage rate was 81% and was at least 76% in those aged 5-14 years. The 7-, 10-, and 13-valent pneumococcal vaccines would cover 37%, 37%, and 49% of children with carriage, respectively. In the multivariate analysis, we identified increase in weight since last visit (p=0.028) and the existence of care-givers who had respiratory symptoms in the past week (p=0.022) as risk factors for carriage. Weight gain was also significantly associated with antiretroviral use (p=0.002). CONCLUSIONS: These data illuminate the little known area of pneumococcal carriage in older HIV-infected children as well as finding novel risk factors for pneumococcal carriage, namely the association with household members who have respiratory symptoms and with an increase in the child's weight prior to swabbing. Weight gain may be due to an increase in health enabling more mobility and increasing the risk of acquiring carriage. The carriage rate observed (81%) is one of the highest recorded. Further research should address whether vaccination can prevent the acquisition of carriage and so protect against disease.
BACKGROUND:Pneumococcal colonization of the nasopharynx is especially common in young children and is a pre-requisite for pneumococcal disease. Those with immunosuppression, such as HIV, are at higher risk of colonization and disease, especially at older ages. Currently, vaccination schedules are only offered to children under 6 months of age, despite the large impact of pneumococcal disease in older unvaccinated children with HIV. We conducted a study to assess the prevalence of, and risk factors for, pneumococcal carriage in HIV-positive children aged <15 years. METHODS: We collected a single nasopharyngeal swab from 142 HIV-infectedchildren aged 1-14 years over a 2-month period. To detect carriage of pneumococcus, these samples were cultured and serotyped; PCR was performed on negative samples. We also collected epidemiological data via survey and medical records. RESULTS: The overall carriage rate was 81% and was at least 76% in those aged 5-14 years. The 7-, 10-, and 13-valent pneumococcal vaccines would cover 37%, 37%, and 49% of children with carriage, respectively. In the multivariate analysis, we identified increase in weight since last visit (p=0.028) and the existence of care-givers who had respiratory symptoms in the past week (p=0.022) as risk factors for carriage. Weight gain was also significantly associated with antiretroviral use (p=0.002). CONCLUSIONS: These data illuminate the little known area of pneumococcal carriage in older HIV-infectedchildren as well as finding novel risk factors for pneumococcal carriage, namely the association with household members who have respiratory symptoms and with an increase in the child's weight prior to swabbing. Weight gain may be due to an increase in health enabling more mobility and increasing the risk of acquiring carriage. The carriage rate observed (81%) is one of the highest recorded. Further research should address whether vaccination can prevent the acquisition of carriage and so protect against disease.
Authors: K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: Louise K Francois Watkins; Jennifer L Milucky; Lesley McGee; Florence Siné St-Surin; Pengbo Liu; Theresa Tran; Sopio Chochua; Gerard Joseph; Nong Shang; Stanley Juin; Patrick Dely; Roopal Patel; Chris A Van Beneden Journal: J Infect Dis Date: 2021-09-01 Impact factor: 7.759
Authors: Shabir A Madhi; Alane Izu; Marta C Nunes; Avye Violari; Mark F Cotton; Patrick Jean-Philippe; Keith P Klugman; Anne von Gottberg; Nadia van Niekerk; Peter V Adrian Journal: Vaccine Date: 2015-04-21 Impact factor: 3.641
Authors: Eric S Donkor; Jennifer A Annan; Ebenezer V Badoe; Nicholas T K D Dayie; Appiah-Korang Labi; Hans-Christian Slotved Journal: BMC Infect Dis Date: 2017-02-08 Impact factor: 3.090
Authors: Geofrey Makenga; George Mtove; J Kevin Yin; Abubakary Mziray; Veneranda M Bwana; William Kisinza; Julius Mjema; Ben Amos; Laura Antony; Delane Shingadia; Shahin Oftadeh; Robert Booy Journal: Front Immunol Date: 2021-06-17 Impact factor: 7.561
Authors: Richard A Adegbola; Rodrigo DeAntonio; Philip C Hill; Anna Roca; Effua Usuf; Bernard Hoet; Brian M Greenwood Journal: PLoS One Date: 2014-08-01 Impact factor: 3.240
Authors: Laura M Conklin; Godfrey Bigogo; Geofrey Jagero; Lee Hampton; Muthoni Junghae; Maria da Gloria Carvalho; Fabiana Pimenta; Bernard Beall; Thomas Taylor; Brian Plikaytis; Kayla F Laserson; John Vulule; Chris Van Beneden; Cynthia G Whitney; Robert F Breiman; Daniel R Feikin Journal: BMC Infect Dis Date: 2016-01-16 Impact factor: 3.090